Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model. - Wikidata - wikimedia - TriplyDB

Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.

Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.

http://www.wikidata.org/entity/Q37325233

about

The Role of Sulforaphane in Epigenetic Mechanisms, Including Interdependence between Histone Modification and DNA Methylation Protective Effects of Valproic Acid, a Histone Deacetylase Inhibitor, against Hyperoxic Lung Injury in a Neonatal Rat Model Biological significance and therapeutic implication of resveratrol-inhibited Wnt, Notch and STAT3 signaling in cervical cancer cells Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy Transcriptional regulation of E-cadherin and oncoprotein E7 by valproic acid in HPV positive cell lines.Piwil2 is reactivated by HPV oncoproteins and initiates cell reprogramming via epigenetic regulation during cervical cancer tumorigenesis.Transcription regulation of E-cadherin by zinc finger E-box binding homeobox proteins in solid tumors Chromatin remodeler mutations in human cancers: epigenetic implications.Coptis Chinensis affects the function of glioma cells through the down-regulation of phosphorylation of STAT3 by reducing HDAC3.Lactic acid alleviates stress: good for female genital tract homeostasis, bad for protection against malignancy.Vitamin A deficiency impairs spatial learning and memory: the mechanism of abnormal CBP-dependent histone acetylation regulated by retinoic acid receptor alpha.

P2860

Q26772035-01E8A7AE-7968-4FAF-B82E-FC44A82A6DAC Q28546994-3F9E89EA-BE4F-4BD3-97F6-9722771F5AAC Q33925336-2E632453-C1CC-4A00-B4B8-80C36334E31A Q35845089-2C8E787E-F91C-4471-B6F3-925F0F1ED933 Q36882942-402BCBC7-ABE1-4F9C-91A6-1524F93C6F79 Q37110658-1C16BC41-9F45-4D77-BB6B-E7F6E79EFE55 Q37662090-16716D19-A733-43D0-BCE4-E24249377848 Q38246793-56A8F5C1-498B-49A4-995C-5C3CDB45C6BC Q38261746-4D789D4E-E7DB-4FC6-BCFE-7284BCE6565F Q47112935-B656ACF1-8E58-4E97-97B6-81DC2F7265E9 Q47600761-CDE8D643-5621-47B3-B424-DB6D5590BC02 Q50660192-114233D7-9554-442F-B98D-DA4C928DF6B2

P2860

Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.

http://www.wikidata.org/entity/Q37325233

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Targeting of histone deacetyla ...... rvical cancer xenograft model.

@en

Targeting of histone deacetyla ...... rvical cancer xenograft model.

@nl

type

label

Targeting of histone deacetyla ...... rvical cancer xenograft model.

@en

Targeting of histone deacetyla ...... rvical cancer xenograft model.

@nl

prefLabel

Targeting of histone deacetyla ...... rvical cancer xenograft model.

@en

Targeting of histone deacetyla ...... rvical cancer xenograft model.

@nl

P1433

Q37325233-C92F6D35-BD10-4566-BF61-FA8278F78FDB

P1476

Q37325233-F605DCAA-1E43-499A-AEF5-435693155F1F

P2093

Q37325233-08FCBEAD-A2D6-4FC3-A9F2-EFE377910CD5

Q37325233-10D4A326-614A-4F82-9E87-BB710597F5D3

Q37325233-547A2DF0-5B5A-4DE5-A29F-AB3455ABB2AA

Q37325233-5799984B-C405-467A-9EEF-145517259871

Q37325233-5852E0BB-2E04-4AAC-BBB7-62B6079454F3

Q37325233-699A52EA-0F5C-46F4-A673-0C379FDDA91B

Q37325233-7DD45E08-06ED-4425-A2CF-3016A72F14A7

Q37325233-9433BB2C-3ED6-4015-AFCF-BCDDA48996D0

Q37325233-A88867EF-854D-4354-ACA6-7475E26EF38A

Q37325233-DBDB216A-C53C-4031-88E9-02D5422BA4D2

P2860

Q37325233-045087BD-3711-4095-A239-D493C9D871D0

Q37325233-102AEE9A-F4DE-4069-A881-61FEF9713B01

Q37325233-128A3301-DD57-48E2-9987-08AC69D5960B

Q37325233-12FBA80E-F240-4AA7-97F1-24C9F4B4E0A6

Q37325233-1736EBF5-F04A-4DA9-8E23-71B0C024E5DC

Q37325233-19CDC7D1-5C87-4D61-A786-5CE5535DC56D

Q37325233-22C8F1FE-8C64-4FBD-8D5E-BF880C1FAEA8

Q37325233-2516C02D-7298-408E-A201-36DE9E9F164B

Q37325233-280D119E-D941-4044-921C-041C0F62FD6E

Q37325233-3082D4DB-F528-41C0-8848-579EDC46D239

P304

Q37325233-2CBD70D3-CFA4-4DF8-A91A-76CF04904F62

P31

Q37325233-B7D2FA9A-B8F6-41BD-96F3-E4E01F161043

P356

Q37325233-A64A0879-858E-4F01-B2DF-766595F4FC0D

P407

Q37325233-886A1F78-FFD6-43EC-A3E1-198E9F2E3D14

P433

Q37325233-C6529337-0216-480A-BB44-341087B3A21D

P478

Q37325233-7C8653A7-8D75-49CA-A962-0899F0E24F17

P577

Q37325233-40649ADB-0B8B-4C32-B906-738C8AD57DD0

P5875

Q37325233-A6048272-3241-40DB-8D64-343CD734BC41

P698

Q37325233-196B2DA9-7A96-48F0-974F-63D8C7D6934E

P921

Q37325233-BCFCDDA8-080B-4628-A99F-09CA33AB3103

P932

Q37325233-801045CA-7A6E-43FC-B560-3FC730BE3861

P356

JOURNAL.PONE.0080657

P1433

P1476

Targeting of histone deacetyla ...... rvical cancer xenograft model.

@en

P2093

Bin Ling

http://www.w3.org/2001/XMLSchema#string

Chunhong Ma

http://www.w3.org/2001/XMLSchema#string

Dingqing Feng

http://www.w3.org/2001/XMLSchema#string

Haiming Wei

http://www.w3.org/2001/XMLSchema#string

Hu Zhou

http://www.w3.org/2001/XMLSchema#string

Jiao Wu

http://www.w3.org/2001/XMLSchema#string

Weidong Zhao

http://www.w3.org/2001/XMLSchema#string

Weiping Hu

http://www.w3.org/2001/XMLSchema#string

Ying Zhou

http://www.w3.org/2001/XMLSchema#string

Yuan Tian

http://www.w3.org/2001/XMLSchema#string

P2860

E-cadherin/β-catenin complex and the epithelial barrier

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid

Cellular senescence and tumor suppressor gene p16

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells

Nuclear myosin 1c facilitates the chromatin modifications required to activate rRNA gene transcription and cell cycle progression

Role of the histone deacetylase complex in acute promyelocytic leukaemia

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

Molecular requirements for epithelial-mesenchymal transition during tumor progression

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

P304

e80657

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0080657

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258826331

http://www.w3.org/2001/XMLSchema#string

P698

24260446

http://www.w3.org/2001/XMLSchema#string

P921

P932

3834007

http://www.w3.org/2001/XMLSchema#string